Article
RegenXBio gets FDA support for Hunter syndrome gene therapy's accelerated review filing—in 2024
Rating:
0.0
Views:
45
Likes:
1
Library:
1
It's going to be a long wait, but RegenXBio is already waving a flag to show that the Hunter syndrome gene therapy RGX-121 is headed for an accelerated approval request at the FDA. | It's going to be a long wait, but RegenXBio is already waving a flag to show that the Hunter syndrome gene therapy RGX-121 is headed for an accelerated approval request at the FDA.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value